BIIB - Shaky Prospects For Eli Lilly's Donanemab For Alzheimer's Disease

• At this point, Eli Lilly's donanemab performs only a tick better than Biogen's aducanumab/Aduhelm for Alzheimer's disease.
• The FDA may grant accelerated approval to donanemab as it did for aducanumab based on the removal of amyloid plaques as a surrogate biomarker.
• Medicare, though, will probably deny general coverage to donanemab as it did for Aduhelm based on insufficient clinical evidence.
• Investors should consider selling some shares of Eli Lilly given this likely outcome.

For further details see: